Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?


Organovo (ONVO) Leaps on Positive 3D Liver Tissue Data

By  +Follow October 22, 2013 7:47AM
Tickers Mentioned:

Shares in Organovo (ONVO) leapt over 8 percent in early trading on Tuesday, with the catalyst coming when the company presented data showing that their 3D, bioprinted liver tissue could retain key liver functions for up to 40 days. The gains continue a strong year for Organovo, which has added over 150 percent since the beginning of 2013.

3D Bioprinting Should Benefit Drug Studies

Organovo uses bioprinting technology that layers human cells to create functional human tissue. The long-term goal would be to create functional human organs, but the near-term goals are focused on creating technology for use in research and testing. Organovo’s 3D bioprinted tissue can be used in testing the toxicity of experimental pharmaceuticals early in the R&D process, allowing pharmaceutical companies to potentially save billions on drug development by identifying issues with experimental drugs before bringing them to clinical trials.

The data, which is being presented at the 3rd Annual Cell Therapy Bioprocessing Conference, also showed that Organovo’s liver tissue demonstrated dose-dependent to acetaminophen, a liver-toxicant, meaning the tissue could be used to assess toxicology issues for a human liver.

Results Are Ahead of Schedule

The results for the bioprinted liver tissue demonstrate that Organovo’s concepts are coming much sooner than previously anticipated. Earlier timelines gave Organovo until the end of the year to produce results like these. The company remains on track for a 2014 launch of their 3D human liver product.

"This additional functional validation of Organovo's 3D Liver continues the demonstration of strong performance of these tissues," said CEO Keith Murphy.  "In April we were able to show that liver function was retained in our 3D Liver for over five days, and we have now demonstrated that our tissues perform consistently for at least 40 days, a significant improvement over the average 48 hour performance of 2D cultures.  The stable, liver-specific functionality of 3D Liver is consistent with our observations that other NovoGen bioprinted tissues become fully cellular, steady state, living tissues that persist over time.  Furthermore, the fact that these tissues demonstrate similar activity to native liver when presented with a known challenge drug is an encouraging indication of utility in drug development."

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions.

Liked What You Read? Join Equities.com as a contributor and get eyeballs on your content FOR FREE!

By  +Follow October 22, 2013 7:47AM



blog comments powered by Disqus

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.